News

​Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

10 June 2025

Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors

24 January 2025

Nuevocor will present and participate in a panel discussion at the Chardan’s 8th Annual Genetic Medicines Conference – New York City – September 30 - October 1, 2024 

27 September 2024

Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer

11 April 2024

Nuevocor to Present at Biotech Showcase during JPM week and at Keystone Symposium on Heart Development and Disease

21 December 2022

Nuevocor Founders to Present at the American Society of Gene and Cell Therapy (ASGCT) 2022 Meeting

18 April 2022

Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Lead Asset

6 May 2025

Nuevocor to present at European Society for Gene and Cell Therapy (ESGCT) 31st Annual Congress 2024

15 October 2024

Nuevocor won Most Promising Gene Therapy Pipeline in APAC at the Asia Pacific Cell & Gene Therapy Excellence Awards 2024 through public voting

18 September 2024

Nuevocor presents pre-clinical data at ESGCT and AHA meetings

7 November 2023

Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022

28 October 2022

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

18 June 2021